Cancer stem cells in head and neck squamous cell carcinoma: A review of current knowledge and future applications

Head and Neck

Volumn 34, Issue 6, 2012, Pages 894-899

  Bhaijee, Feriyl ^a   Pepper, Dominique J ^a   Pitman, Karen T ^b   Bell, Diana ^a,c  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

aldehyde dehydrogenase; BMI 1; cancer stem cell; CD44; head and neck squamous cell carcinoma

Indexed keywords

ALDEHYDE DEHYDROGENASE; BIOLOGICAL MARKER; HERMES ANTIGEN;

CANCER GROWTH; CANCER MORTALITY; CANCER RESISTANCE; CANCER STEM CELL; CELLULAR DISTRIBUTION; GENE EXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; METASTASIS; MOLECULAR IMAGING; MORBIDITY; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

ANTIGENS, CD44; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; ISOENZYMES; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; RETINAL DEHYDROGENASE;

EID: 84861331796     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21801     Document Type: Review

References (63)

1. Boyle P, Levin B, eds. World cancer report 2008. Lyon, France: WHO IARC Press.
2. Haddad RI, Shin DM,. Recent advances in head and neck cancer. N Engl J Med 2008; 359: 1143-1154.
3. Heppner G, Yamashina K, Miller B, Miller F,. Tumor heterogeneity in metastasis. Prog Clin Biol Res 1986; 212: 45-59.
4. Reya T, Morrison SJ, Clarke MF, Weissman IL,. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
5. Tang DG, Patrawala L, Calhoun T, et al. Prostate cancer stem/progenitor cells: identification, characterization, and implications. Mol Carcinog 2007; 46: 1-14.
6. Odoux C, Fohrer H, Hoppo T, et al. A stochastic model for cancer stem cell origin in metastatic colon cancer. Cancer Res 2008; 68: 6932-6941.
7. Visvader JE, Lindeman GJ,. Stem cells and cancer: the promise and puzzles. Mol Oncol 2010; 4: 369-372.
8. Chen ZG,. The cancer stem cell concept in progression of head and neck cancer. J Oncol 2009; 2009: 894064.
9. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells: perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006; 66: 9339-9344.
10. Dalerba P, Cho RW, Clarke MF,. Cancer stem cells: models and concepts. Ann Rev Med 2007; 58: 267-284.
11. Visvader JE, Lindeman GJ,. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-768.
12. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100: 3983-3988.
13. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
14. Collins AT, Berry PA, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-10951.
15. Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008; 15: 504-514.
16. Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007; 104: 10158-10163.
17. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-323.
18. Yang ZF, Ho DW, Ng MN, et al. Significance of CD90 cancer stem cells in human liver cancer. Cancer Cell 2008; 13: 153-166.
19. Fang D, Nguyen TK, Leishear K, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005; 65: 9328-9337.
20. Abbas O, Richards JE, Yaar R, Mahalingam M,. Stem cell markers (cytokeratin 15, cytokeratin 19 and p63) in in situ and invasive cutaneous epithelial lesions. Mod Pathol 2011; 24: 90-97.
21. Charafe-Jauffret E, Monville F, Ginestier C, et al. Cancer stem cells in breast: current opinion and future challenges. Pathobiology 2008; 75: 75-84.
22. Wicha MS, Liu S, Dontu G,. Cancer stem cells: an old ideaa paradigm shift. Cancer Res 2006; 66: 1883-1890.
23. Brabletz T, Jung A, Spaderna S, et al. Opinion: migrating cancer stem cells. An integrated concept of malignant tumor progression. Nat Rev Cancer 2005; 5: 744-749.
24. Iwatsuki M, Mimori K, Yokobori T, et al. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci 2010; 101: 293-299.
25. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
26. Hermann PC, Bhaskar S, Cioffi M, Heeschen C,. Cancer stem cells in solid tumors. Semin Cancer Biol 2010; 20: 77-84.
27. Goodell MA, Brose K, Paradis G, et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996; 183: 1797-1806.
28. Dell'Albani P,. Stem cell markers in gliomas. Neurochem Res 2008; 33: 2407-2415.
29. Dean M, Fojo T, Bates S,. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-284.
30. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 2004; 101: 14228-14233.
31. Prince ME, Ailles LE,. Cancer stem cells in head and neck squamous cell carcinoma. J Clin Oncol 2008; 26: 2871-2875.
32. Todaro M, Zerilli M, Ricci-Vitiani L, et al. Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells. Cancer Res 2006; 66: 1491-1499.
33. Tan AR, Alexe G, Reiss M,. Transforming growth factor-β signaling: emerging stem cell target in metastatic breast cancer? Breast Cancer Res Treat 2009; 115: 453-495.
34. Clay MR, Tabor M, Owen JH, et al. Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck 2010; 32: 1195-1201.
35. Pene F, Courtine E, Cariou A, Mira JP,. Toward theragnostics. Crit Care Med 2009; 37 (Suppl 1): S50-S58.
36. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007; 104: 973-978.
37. Rudzki Z, Jothy S,. CD44 and the adhesion of neoplastic cells. Mol Pathol 1997; 50: 57-71.
38. Mack B, Gires O,. CD44s and CD44v6 expression in head and neck epithelia. PLoS ONE 2008; e3360.
39. Chen YC, Chen YW, Hsu HS, et al. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun 2009; 385: 307-313.
40. Krishnamurthy S, Dong Z, Vodopyanov D, et al. Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. Cancer Res 2010; 70: 9969-9979.
41. Yoshida A,. Molecular genetics of human aldehyde dehydrogenase. Pharmacogenetics 1992; 2: 139-147.
42. Duester G,. Families of retinoid dehydrogenases regulating vitamin A function: production of visual pigment and retinoic acid. Eur J Biochem 2004; 267: 4315-4324.
43. Lindahl R,. Aldehyde dehydrogenases and their role in carcinogenesis. Crit Rev Biochem Mol Biol 1992; 27: 283-335.
44. Armstrong L, Stojkovic M, Dimmick L, et al. Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. Stem Cells 2004; 22: 1142-1151.
45. Hess DA, Meyerrose TE, Wirthlin L, et al. Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood 2004; 104: 1648-1655.
46. Pearce DJ, Taussig D, Simpson C, et al. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells 2005; 23: 752-760.
47. Visus C, Ito D, Amoscato A, et al. Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck. Cancer Res 2007; 67: 10538-10545.
48. Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004; 103: 2332-2336.
49. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and as a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-567.
50. Ma S, Chan KW, Lee TK, et al. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell population. Mol Cancer Res 2008; 6: 1146-1153.
51. Huang EJ, Hynes MJ, Zhang T, et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colon stem cells (SC) and tracks SC overpopulation during colonic tumorigenesis. Cancer Res 2009; 69: 3382-3389.
52. Jiang F, Qui Q, Khanna A, et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 2009; 7: 330-338.
53. Zhou BP, Deng J, Xia W, et al. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 2004; 6: 931-940.
54. Davis SJ, Divi V, Owen JH, et al. Metastatic potential of cancer stem cells in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2010; 136: 1260-1266.
55. Takahashi E, Nagano O, Ishimoto T, et al. Tumor necrosis factor-alpha regulates transforming growth factor-beta-dependent epithelial-mesenchymal transition by promoting hyaluronan-CD44-moesin interaction. J Biol Chem 2010; 285: 4060-4073.
56. Park I, Morrison SJ, Clarke ML,. Bmi1, stem cells, and senescence regulation. J Clin Invest 2004; 113: 175-179.
57. Park I, Qian D, Kiel M, et al. Bmi-1 is required for maintenance of adult self-renewing hematopoietic stem cells. Nature 2003; 423: 302-305.
58. Molofsky A, Pardal R, Iwashita T, et al. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 2003; 425: 962-967.
59. Glinsky GV, Berezovska O, Glinskii AB,. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005; 115: 1503-1521.
60. Fuchs E, Tumbar T, Guasch G,. Socializing with the neighbors: stem cells and their niche. Cell 2004; 116: 769-778.
61. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007; 11: 69-82.
62. Sugiyama T, Kohara H, Noda M, Nagasawa T,. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006; 25: 977-988.
63. Folkins C, Man S, Xu P, et al. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 2007; 67: 3560-3564.